search
Back to results

Patients Perceptions of Using the "Libre" System Compared With Conventional SMBG in Adolescents With Type 1 Diabetes The Libre Sat Trial

Primary Purpose

Type 1 Diabetes

Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Libre Flash CGMS
Self-Measurement Blood Glucose
Sponsored by
Rabin Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 1 Diabetes focused on measuring Continuous Glucose Monitoring System

Eligibility Criteria

12 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The subject has documented Type 1 Diabetes , as defined by the American Diabetes Association and World Health Organization for at least 1 year prior to study enrollment
  • The subject used continuous glucose monitoring until 3 months or more before the study start
  • Age 12-17 years
  • The subject has an HbA1c value > 7.5% at time of screening visit
  • The subject is willing to follow study instructions
  • Subject is available for entire study duration

Exclusion Criteria:

  • Concomitant diseases that influence metabolic control or other medical condition, which in the Investigator's opinion, may compromise patient safety
  • Significant co-morbidity that, in the opinion of the investigators would preclude participation in the study
  • Any significant diseases or conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patient's safety
  • Subject is taking or has taken oral or parenteral glucocorticoids within 1 month prior to screening, or plans to take oral or parenteral glucocorticoids within the planned study duration. Exceptions: Short term oral or parenteral glucocorticoids up to 7 days
  • Subject has known allergy to medical grade adhesives
  • Subject is participating in another study of a medical device or drug that could affect glucose measurements or glucose management or receipt of any investigational medical product within 1 month prior to screening
  • Female subject of child-bearing potential who have a positive pregnancy test at screening, is pregnant, breast-feeding, or planning to become pregnant within the planned study duration or is not using adequate contraceptive methods
  • Subject diagnosed with current eating disorder such as anorexia or bulimia
  • Subject has a history of one or more episodes of Diabetes Keto-Acidosis requiring hospitalization within a month prior to screening
  • Subject has unstable or rapidly progressive renal disease or is receiving dialysis
  • Subject has active proliferating retinopathy
  • Subject has current or recent history of alcohol or drug abuse
  • Subject has visual impairment or hearing loss, which in the Investigator's opinion, may compromise patient ability to perform study procedures safely
  • Any disease or condition that may influence the HbA1C testing

Sites / Locations

  • Schneider Children's Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Libre Flash CGMS (Continuous Monitoring System)

SMBG

Arm Description

Patients will use the Libre Flash Continuous Glucose Monitoring System for 12 weeks for their glucose Management

Patients will use Self-Monitoring of Blood Glucose for 12 weeks for their glucose management

Outcomes

Primary Outcome Measures

Diabetes Treatment satisfaction questionnaire
Libre-user evaluation questionnaire
20-item questionnaire that asses treatment satisfaction with the Libre including ease of use, comfort, pain, design and system operation. The questionnaire will be scored to a final score integrating all items to a total score

Secondary Outcome Measures

Glycemic control measured by HbA1c

Full Information

First Posted
April 12, 2016
Last Updated
August 8, 2022
Sponsor
Rabin Medical Center
Collaborators
Abbott
search

1. Study Identification

Unique Protocol Identification Number
NCT02776007
Brief Title
Patients Perceptions of Using the "Libre" System Compared With Conventional SMBG in Adolescents With Type 1 Diabetes The Libre Sat Trial
Official Title
Patients Perceptions of Using the Libre System Compared With Conventional SMBG in Adolescents With Type 1 Diabetes The Libre Sat Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
July 2016 (Actual)
Primary Completion Date
April 30, 2020 (Actual)
Study Completion Date
April 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rabin Medical Center
Collaborators
Abbott

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The Libre- flash glucose monitoring system is an episodic real-time data on demand device. This means that patients can measure their glucose level when they choose by scanning the device, while at the same time a sensor automatically measures and continuously stores glucose readings day and night. Every scan shows the current glucose reading and the last 8 hours of glucose. There are no alarms and the system does not require calibration. In the present study we aim to evaluate treatment satisfaction and comfort using the Libre flash glucose monitoring system compared to conventional Self Measurement of Blood Glucose (SMBG) in adolescents with type 1 diabetes that discontinued using continuous glucose monitoring. The second aim of the study is to evaluate the rate of use and the impact of Libre use compared to Self-Measurement of Blood Glucose among adolescents who are sub-optimally controlled and stopped using Continuous Glucose Monitoring. The study is an investigator initiated study, single-center, randomized, parallel study of 12 weeks with an optional cross-over 12 weeks extension period .

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
Continuous Glucose Monitoring System

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Libre Flash CGMS (Continuous Monitoring System)
Arm Type
Experimental
Arm Description
Patients will use the Libre Flash Continuous Glucose Monitoring System for 12 weeks for their glucose Management
Arm Title
SMBG
Arm Type
Active Comparator
Arm Description
Patients will use Self-Monitoring of Blood Glucose for 12 weeks for their glucose management
Intervention Type
Device
Intervention Name(s)
Libre Flash CGMS
Intervention Type
Device
Intervention Name(s)
Self-Measurement Blood Glucose
Intervention Description
Patients will use their personal glucose meter to perform Self-Measurement Blood Glucose
Primary Outcome Measure Information:
Title
Diabetes Treatment satisfaction questionnaire
Time Frame
At the final visit- week 12
Title
Libre-user evaluation questionnaire
Description
20-item questionnaire that asses treatment satisfaction with the Libre including ease of use, comfort, pain, design and system operation. The questionnaire will be scored to a final score integrating all items to a total score
Time Frame
At the final visit-week 12
Secondary Outcome Measure Information:
Title
Glycemic control measured by HbA1c
Time Frame
At the final visit-week 12
Other Pre-specified Outcome Measures:
Title
Number of blood glucose measurements at each arm
Time Frame
At the final visit-week 12
Title
Number of flash glucose measurements at the intervention arm
Time Frame
At the final visit-week 12
Title
Percentage of glucose sensor readings within the range of 70 to 180 mg/dl
Time Frame
At the final visit-week 12
Title
Percentage of glucose sensor readings below 60 mg/dl
Time Frame
At the final visit-week 12
Title
Percentage of glucose sensor readings above 240 mg/dl
Time Frame
At the final visit-week 12
Title
Average of glucose sensor readings
Description
Average of glucose sensor readings (per 24 hours)
Time Frame
Week 12
Title
Standard Deviation of glucose sensor readings
Description
Standard Deviation of glucose sensor readings (per 24 hours) )
Time Frame
Week 12
Title
HbA1c change from baseline to the end of the first intervention period
Time Frame
At the final visit-week 12
Title
HbA1c change from baseline to the end of the second intervention period
Time Frame
At the final visit-week 12
Title
Average fasting blood glucose level
Time Frame
At the final visit-week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The subject has documented Type 1 Diabetes , as defined by the American Diabetes Association and World Health Organization for at least 1 year prior to study enrollment The subject used continuous glucose monitoring until 3 months or more before the study start Age 12-17 years The subject has an HbA1c value > 7.5% at time of screening visit The subject is willing to follow study instructions Subject is available for entire study duration Exclusion Criteria: Concomitant diseases that influence metabolic control or other medical condition, which in the Investigator's opinion, may compromise patient safety Significant co-morbidity that, in the opinion of the investigators would preclude participation in the study Any significant diseases or conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patient's safety Subject is taking or has taken oral or parenteral glucocorticoids within 1 month prior to screening, or plans to take oral or parenteral glucocorticoids within the planned study duration. Exceptions: Short term oral or parenteral glucocorticoids up to 7 days Subject has known allergy to medical grade adhesives Subject is participating in another study of a medical device or drug that could affect glucose measurements or glucose management or receipt of any investigational medical product within 1 month prior to screening Female subject of child-bearing potential who have a positive pregnancy test at screening, is pregnant, breast-feeding, or planning to become pregnant within the planned study duration or is not using adequate contraceptive methods Subject diagnosed with current eating disorder such as anorexia or bulimia Subject has a history of one or more episodes of Diabetes Keto-Acidosis requiring hospitalization within a month prior to screening Subject has unstable or rapidly progressive renal disease or is receiving dialysis Subject has active proliferating retinopathy Subject has current or recent history of alcohol or drug abuse Subject has visual impairment or hearing loss, which in the Investigator's opinion, may compromise patient ability to perform study procedures safely Any disease or condition that may influence the HbA1C testing
Facility Information:
Facility Name
Schneider Children's Medical Center
City
Petach-Tikva
ZIP/Postal Code
49202
Country
Israel

12. IPD Sharing Statement

Learn more about this trial

Patients Perceptions of Using the "Libre" System Compared With Conventional SMBG in Adolescents With Type 1 Diabetes The Libre Sat Trial

We'll reach out to this number within 24 hrs